Acquired FXIII Deficiency is Associated with High Morbidity

Area of Science:

• Hematology
• Clinical Medicine
• Coagulation Disorders

Background:

• A factor XIII (FXIII) level >30% is typically considered necessary to prevent spontaneous bleeding.
• The precise hemostatic level of FXIII in acquired deficiency remains undetermined.

Purpose of the Study:

• To identify the optimal cut-off for FXIII activity in acquired deficiency.
• To distinguish between low and high risk of major bleeding in a mixed population.

Main Methods:

• Retrospective analysis of patients with acquired FXIII deficiency over 3 years.
• Assessment of clinical data to correlate FXIII activity with bleeding risk.
• Study ID NCT04416594, registered at http://www.clinicaltrials.gov.

Main Results:

• Among 97 bleeding patients with normal coagulation, 43.2% had FXIII activity <70%.
• FXIII activity was notably lower in surgical and ICU patients.
• Low FXIII activity correlated with prolonged ICU stays and increased major bleeding.

Conclusions:

• Acquired FXIII deficiency is linked to significant patient morbidity.
• The hemostatic FXIII level in acquired deficiency may exceed the standard 30% threshold.